GREENWICH, Conn., Aug. 01, 2017 -- TICC Capital Corp. (Nasdaq:TICC) announced today that it will hold a conference call to discuss second quarter 2017 earnings on Tuesday, August 8, 2017 at 10:00 AM. The toll free dial-in number will be 1-888-339-0740. There will be a recording available for 30 days. If you are interested in hearing the recording, please dial 1-877-344-7529. The replay pass-code number is 10111238.
About TICC Capital Corp.
TICC Capital Corp. is a publicly-traded business development company principally engaged in providing capital to established businesses, investing in syndicated bank loans and purchasing debt and equity tranches of collateralized loan obligation vehicles.
Forward-Looking Statements
This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events.
Contact: Bruce Rubin 203-983-5280


Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 



